Study by Electroencephalography of the Link Between the Lack of Self-compassion and the Disorder of Empathy in Schizophrenia
NCT ID: NCT05464563
Last Updated: 2024-08-20
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
60 participants
INTERVENTIONAL
2022-03-22
2024-01-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It will be a question of better understanding the neuro-functional mechanisms which underlie the lack of self-compassion and the disorder of empathy in schizophrenia, the relationship that these disorders maintain between them but also the relationship that they maintain with the general psychopathology of schizophrenia and, in particular, with the abnormalities of the self. In other words, the overall framework of this project is that of the link between the psychopathology of schizophrenia and the functional impairment associated with it. Its specific field of application is that of the link between self-awareness disorders, self-compassion deficit and empathy disorder. For this, this project proposes a methodological approach combining the recording of intrinsic and extrinsic brain activity using high-density electroencephalography (EEG).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Electrophysiological Markers Related to the Cognitive and Affective Processes Behind Empathic Behaviour in Schizophrenic Spectrum Disorder
NCT04278339
EEG and Behavioral Correlates of Temporal Prediction in the Tactile Modality in Schizophrenia
NCT05296720
Interest of EMDR Schizophrenic Disorders
NCT05164289
Mindfulness, Empathy and the Oxytocinergic System in Persons With Schizophrenia
NCT05491486
Auditory Processes and Emotional Perception in Schizophrenia
NCT04768335
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
At inclusion visit, participants have:
* a psychiatric evaluation;
* self evaluation of: empathy, self-compassion, émotionnel processing, anxiety, insight, perceptual aberration and quality of life;
* training to practise of self-compassion and empathy (for patients only).
During the phase of experimentation, the participants have electroencephalogram exams during a rest phase, a self-compasion task and an empathy task.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Patient group
Patients have electroencephalogram records during :
* a phase of rest;
* a task of self-compassion
* a task of empathy.
Electroencephalogram
An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
Control group
Healthy volunteers have electroencephalogram records during :
* a phase of rest;
* a task of self-compassion
* a task of empathy.
Electroencephalogram
An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Electroencephalogram
An electroencephalogram is recorded during a task of rest then self-compassion and then empathy.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patients stabilized for at least 3 months for their psychotic disorders
* patients with disease duration \> 2 years but \< 20 years
* patients whose treatment has not been changed or modified in the previous month
* patients on stable treatments who should not change treatment during the study (good compliance, good tolerance)
* patients who do not benefit from a neuromodulation protocol for their symptoms (rTMS, TDCS)
* patients who do not benefit from a cognitive remediation program
* patients between the ages of 18 and 60
* men and women
* patients with normal or corrected vision
* patients without mental impairment
* patients without neurological impairment (epilepsy, encephalopathy, head trauma)
* patients with a sufficient command of French
* patients free or under protective measures
* patients benefiting from coverage by a social security scheme or benefiting from it through a third party
* Having given their consent to participate in the study after having received written, clear and fair information (and after obtaining the consent of the tutor/curator if applicable)
* healthy volunteers without schizophrenic or schizoaffective disorder and without other psychiatric pathologies as defined by the DSM 5 (axis 1) (in particular, absence of psychic trauma revealed by the MINI and of PTSD (current as whole life))
* subjects aged 18 to 60
* men and women
* subjects with normal or corrected vision
* subjects without mental impairment
* subjects without neurological impairment (epilepsy, encephalopathy, head trauma)
* free subjects, without guardianship or curatorship or subordination
* subjects benefiting from coverage by a social security scheme or benefiting from it through a third party
* Having given their consent to participate in the study after having received written, clear and honest information.
Exclusion Criteria
* patients with an addiction to alcohol or other toxic substances, except tobacco
* patients with suicidal intentionality
* patients not stabilized for their psychotic disorders and with regard to their antipsychotic treatments
* patients receiving antiepileptic treatment with mood-regulating, antidepressant and anxiolytic properties
* patients receiving benzodiazepine treatment that they could not stop 72 hours before the EEG
* patients with disease duration \< 2 years or \> 20 years
* patients with an IQ \< 70
* patients benefiting from a neuromodulation protocol (rTMS, TDCS)
* patients benefiting from a cognitive remediation program
* patients with a PANSS \> or = 5 for items G8 (hostility) and P7 (non-cooperation)
* patients aged \< 18 years or \> 60 years
* patients with mental impairment
* patients with neurological impairment (epilepsy, encephalopathy, head trauma)
* patients with documented neurological pathology or medical condition that may explain the psychotic manifestations
* patients who do not speak French well enough
* subjects residing within a radius greater than 50 km from the hospital
* patients hospitalized under duress
* patients without social security
* subjects with a psychiatric pathology as defined in the DSM-5 (axis 1) (in particular, psychic trauma revealed by the MINI and symptoms of PTSD (current as lifetime))
* subjects aged \< 18 years or \> 60 years
* subjects with a mental deficiency
* subjects with neurological pathology
* subjects with a medical condition preventing them from participating in the study
* subjects residing within a radius greater than 50 km from the hospital
* subjects under guardianship or curatorship
* subjects not benefiting from a Social Security scheme or not benefiting from it through a third party
18 Years
60 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Henri Laborit
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Centre Hospitalier Henri Laborit
Poitiers, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2021-A01913-38
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.